10.17037/DATA.00005133
This dataset contains longitudinal serological data from a study nested within the POPVAC B randomised, double-blind, placebo-controlled trial conducted among school-aged children in Uganda. It includes participant demographics, malaria infection status, and SARS-CoV-2 antibody measurements (spike and nucleocapsid IgG) collected at multiple timepoints before and after COVID-19 vaccination. Data capture exposure to intermittent preventive treatment with dihydroartemisinin–piperaquine or placebo, as well as COVID-19 vaccination status and timing. The dataset supports analyses of SARS-CoV-2 seroprevalence, antibody responses, and fold changes in relation to malaria chemoprevention and vaccination in a malaria-endemic setting.
The dataset contains the 93 variables outlined below.
| Variable Name | Variable Label | Answer Label | Answer Code | Variable Type |
| sex_b | Participant sex | Numeric | ||
| Male | 1 | |||
| Female | 2 | |||
| age_b | Participant age (in years) | Open ended | Numeric | |
| schnm_b | School ID | Numeric | ||
| School 1 | 1 | |||
| School 2 | 2 | |||
| School 3 | 3 | |||
| School 4 | 4 | |||
| School 5 | 5 | |||
| School 6 | 6 | |||
| School 7 | 7 | |||
| School 8 | 8 | |||
| bcgscar_b | BCG scar | Numeric | ||
| absent | 0 | |||
| present | 1 | |||
| uncertain | 98 | |||
| trialarm_b | Trial arm | Numeric | ||
| Placebo | 0 | |||
| DP | 1 | |||
| covid_vaccinated_b | Have you been vaccinated for covid | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| h_doses_b | Highest dose of covid vaccination | Open ended | Numeric | |
| dpd1_wpre6_b | dp/placebo dose 1 admin 6 weeks before BCG | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_wpre6_b | dp/placebo dose 2 admin 6 weeks before BCG | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_wpre6_b | dp/placebo dose 3 admin 6 weeks before BCG | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_wpre2_b | dp/placebo dose 1 admin 2 weeks before BCG | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_wpre2_b | dp/placebo dose 2 admin 2 weeks before BCG | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_wpre2_b | dp/placebo dose 3 admin 2 weeks before BCG | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w2_b | dp/placebo dose 1 admin week 2 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w2_b | dp/placebo dose 2 admin week 2 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w2_b | dp/placebo dose 3 admin week 2 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w6_b | dp/placebo dose 1 admin week 6 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w6_b | dp/placebo dose 2 admin week 6 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w6_b | dp/placebo dose 3 admin week 6 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w10_b | dp/placebo dose 1 admin week 10 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w10_b | dp/placebo dose 2 admin week 10 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w10_b | dp/placebo dose 3 admin week 10 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w14_b | dp/placebo dose 1 admin week 14 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w14_b | dp/placebo dose 2 admin week 14 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w14_b | dp/placebo dose 3 admin week 14 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w18_b | dp/placebo dose 1 admin week 18 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w18_b | dp/placebo dose 2 admin week 18 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w18_b | dp/placebo dose 3 admin week 18 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w22_b | dp/placebo dose 1 admin week 22 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w22_b | dp/placebo dose 2 admin week 22 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w22_b | dp/placebo dose 3 admin week 22 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w26_b | dp/placebo dose 1 admin week 26 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w26_b | dp/placebo dose 2 admin week 26 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w26_b | dp/placebo dose 3 admin week 26 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w30_b | dp/placebo dose 1 admin week 30 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w30_b | dp/placebo dose 2 admin week 30 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w30_b | dp/placebo dose 3 admin week 30 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w34_b | dp/placebo dose 1 admin week 34 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w34_b | dp/placebo dose 2 admin week 34 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w34_b | dp/placebo dose 3 admin week 34 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w38_b | dp/placebo dose 1 admin week 38 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w38_b | dp/placebo dose 2 admin week 38 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w38_b | dp/placebo dose 3 admin week 38 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w42_b | dp/placebo dose 1 admin week 42 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w42_b | dp/placebo dose 2 admin week 42 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w42_b | dp/placebo dose 3 admin week 42 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w46_b | dp/placebo dose 1 admin week 46 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w46_b | dp/placebo dose 2 admin week 46 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w46_b | dp/placebo dose 3 admin week 46 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd1_w50_b | dp/placebo dose 1 admin week 50 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd2_w50_b | dp/placebo dose 2 admin week 50 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| dpd3_w50_b | dp/placebo dose 3 admin week 50 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| pzq_w8_b | pzq admin week 8 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| alb_w8_b | Albendazole admin week 8 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| alb_w28_b | Albendazole admin week 28 | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| completed_b | Participant completed study | Numeric | ||
| No | 0 | |||
| Yes | 1 | |||
| pfal_res_screen_b | P. falciparum PCR result, screening timepoint | String | ||
| Negative | 0 | |||
| Positive | 1 | |||
| pfal_res_wk0_b | P. falciparum PCR result, week 0 timepoint | String | ||
| Negative | 0 | |||
| Positive | 1 | |||
| pfal_res_wk4_b | P. falciparum PCR result, week 4 timepoint | String | ||
| Negative | 0 | |||
| Positive | 1 | |||
| pfal_res_wk8_b | P. falciparum PCR result, week 8 timepoint | String | ||
| Negative | 0 | |||
| Positive | 1 | |||
| pfal_res_wk28_b | P. falciparum PCR result, week 28 timepoint | String | ||
| Negative | 0 | |||
| Positive | 1 | |||
| pfal_res_wk52_b | P. falciparum PCR result, week 52 timepoint | String | ||
| Negative | 0 | |||
| Positive | 1 | |||
| sm_screening_caa_pcr_b | Schistosoma Mansoni Circulating Anodic Antigen and PCR results at baseline | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| bmi_b | Body Mass Index | Open ended | Numeric | |
| Sconc_wk0 | POPVAC B wk0 IgG, S protein, Arbitrary ELISA Units (AEU) | Open ended | Numeric | |
| Nconc_wk0 | POPVAC B wk0 IgG, N protein, AEU | Open ended | Numeric | |
| Sconc_wk4 | POPVAC B wk4 IgG, S protein, AEU | Open ended | Numeric | |
| Nconc_wk4 | POPVAC B wk4 IgG, N protein, AEU | Open ended | Numeric | |
| Sconc_wk8 | POPVAC B wk8 IgG, S protein, AEU | Open ended | Numeric | |
| Nconc_wk8 | POPVAC B wk8 IgG, N protein, AEU | Open ended | Numeric | |
| Sconc_wk52 | POPVAC B wk52 IgG, S protein, AEU | Open ended | Numeric | |
| Nconc_wk52 | POPVAC B wk52 IgG, N protein, AEU | Open ended | Numeric | |
| moccupation_category1 | Mother's occupation | Numeric | ||
| Employed | 1 | |||
| Unemployed | 2 | |||
| Housewives | 3 | |||
| Died/Don't Know | 4 | |||
| post_bin_Sconc_wk0 | S-Antibody Seroposivity at week 0 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Sconc_wk4 | S-Antibody Seroposivity at week 4 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Sconc_wk8 | S-Antibody Seroposivity at week 8 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Sconc_wk52 | S-Antibody Seroposivity at week 52 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Nconc_wk0 | N-Antibody Seroposivity at week 0 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Nconc_wk4 | N-Antibody Seroposivity at week 4 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Nconc_wk8 | N-Antibody Seroposivity at week 8 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| post_bin_Nconc_wk52 | N-Antibody Seroposivity at week 52 | Numeric | ||
| Negative | 0 | |||
| Positive | 1 | |||
| Not recorded | - | |||
| seropositive_status_wk0 | S- and N-Antibody combined Seroposivity at week 0 | Numeric | ||
| Not Infected | 0 | |||
| Infected | 1 | |||
| seropositive_status_wk4 | S- and N-Antibody combined Seroposivity at week 4 | Numeric | ||
| Not Infected | 0 | |||
| Infected | 1 | |||
| seropositive_status_wk8 | S- and N-Antibody combined Seroposivity at week 8 | Numeric | ||
| Not Infected | 0 | |||
| Infected | 1 | |||
| seropositive_status_wk52 | S- and N-Antibody combined Seroposivity at week 52 | Numeric | ||
| Not Infected | 0 | |||
| Infected | 1 | |||
| log_Sconc_wk0 | SARS-CoV-2 log S-antibody levels at week 0 | Open ended | Numeric | |
| log_Sconc_wk4 | SARS-CoV-2 log S-antibody levels at week 4 | Open ended | Numeric | |
| log_Sconc_wk8 | SARS-CoV-2 log S-antibody levels at week 8 | Open ended | Numeric | |
| log_Sconc_wk52 | SARS-CoV-2 log S-antibody levels at week 52 | Open ended | Numeric | |
| log_Nconc_wk0 | SARS-CoV-2 log N-antibody levels at week 0 | Open ended | Numeric | |
| log_Nconc_wk4 | SARS-CoV-2 log N-antibody levels at week 4 | Open ended | Numeric | |
| log_Nconc_wk8 | SARS-CoV-2 log N-antibody levels at week 8 | Open ended | Numeric | |
| log_Nconc_wk52 | SARS-CoV-2 log N-antibody levels at week 52 | Open ended | Numeric |